Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity

Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity

Abstract An effective vaccine against hepatitis C virus (HCV) must elicit the production of broadly neutralizing antibodies (bnAbs) reproducibly against the E1E2 glycoprotein complex. Little is known about how glycan content affects this process. Ideally, glycans would maximize epitope exposure with...

Full description

Saved in:
Bibliographic Details
Main Authors: Liudmila Kulakova, Kiki H. Li, Austin W. T. Chiang, Michael P. Schwoerer, Saori Suzuki, Sanne Schoffelen, Khadija H. Elkholy, Kinlin L. Chao, Salman Shahid, Bhoj Kumar, Nathan B. Murray, Stephanie Archer-Hartmann, Parastoo Azadi, Bjørn G. Voldborg, Alexander Marin, Roy A. Mariuzza, Alexander K. Andrianov, Alexander Ploss, Nathan E. Lewis, Eric A. Toth, Thomas R. Fuerst
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01161-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items